AstraZeneca and BMS held merger talks, Incubate's John Stanford on fixing the US pharma ecosystem, and why real-time clinical trial data matters. Welcome to Pharmaceutical Executive Daily, your quick ...

Rumored tie-up implies acquirer skepticism versus target premium, with AstraZeneca shares falling sharply while BMS rose, reflecting concerns about value transfer and integration risk. A major ...

The Swiss generic drugmaker says the agreement carries no admission of wrongdoing and will not affect its 2026 guidance or mid-term outlook. Sandoz Inc. and its subsidiary Fougera Pharmaceuticals Inc.

This past May, Pharmaceutical Executive reported that CVS Health decided to return Eli Lilly’s Zepbound to its list of ...

Pharmaceutical Executive spoke with Dr. Richard Graham, chairman and co-founder of TruTechnologies about FDA’s new program ...

This past May, Pharmaceutical Executive reported that CVS Health decided to return Eli Lilly’s Zepbound to its list of ...

Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) announced that FDA granted approval of Simtriyo (centanafadine), a once-daily extended-release ...

Specialty pharma launches depend heavily on data from outside the organization. Distributors, third-party logistics providers ...

Since then, that mindset has continued to grow at AbbVie.

Learn why reshoring and tariff exposure are accelerating the trend toward manufacturing in the market where a product is sold. Understand the significance of the Section 301 investigation into Germany ...

Project Trialblazer prioritizes reducing IND review timelines, but its impact on sponsor behavior may be limited when ...

An FDA advisory panel voted to recommend six of seven unapproved peptides for compounding access, raising concerns about its ...